Purpose: Distinguishing latent tuberculosis infection (LTBI) from active tuberculosis (ATB) is important to control the prevalence of tuberculosis; however, there is currently no effective method. The aim of this study was to discover specific metabolites through fecal untargeted metabolomics to discriminate ATB, individuals with LTBI, and healthy controls (HC) and to probe the metabolic perturbation associated with the progression of tuberculosis.
Patients And Methods: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to comprehensively detect compounds in fecal samples from HC, LTBI, and ATB patients. Differential metabolites between the two groups were screened, and their underlying biological functions were explored. Candidate metabolites were selected and enrolled in LASSO regression analysis to construct diagnostic signatures for discriminating between HC, LTBI, and ATB. A receiver operating characteristic (ROC) curve was applied to evaluate diagnostic value. A nomogram was constructed to predict the risk of progression of LTBI.
Results: A total of 35 metabolites were found to exist differentially in HC, LTBI, and ATB, and eight biomarkers were selected. Three diagnostic signatures based on the eight biomarkers were constructed to distinguish between HC, LTBI, and ATB, demonstrating excellent discrimination performance in ROC analysis. A nomogram was successfully constructed to evaluate the risk of progression of LTBI to ATB. Moreover, 3,4-dimethylbenzoic acid has been shown to distinguish ATB patients with different responses to etiological tests.
Conclusion: This study constructed diagnostic signatures based on fecal metabolic biomarkers that effectively discriminated HC, LTBI, and ATB, and established a predictive model to evaluate the risk of progression of LTBI to ATB. The results provide scientific evidence for establishing an accurate, sensitive, and noninvasive differential diagnosis scheme for tuberculosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505020 | PMC |
| http://dx.doi.org/10.2147/IDR.S422363 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distinguish active tuberculosis with an immune-related signature and molecule subtypes: a multi-cohort analysis.
Sci Rep
November 2024
Department of Respiration, West China Hospital of Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China.
Background: Distinguishing latent tuberculosis infection (LTBI) from active tuberculosis (ATB) is very important. This study aims to analyze cases from multiple cohorts and get the signature that can distinguish LTBI from ATB.
Methods: Thirteen datasets were downloaded from the gene expression omnibus (GEO) database.
Specific human gene expression in response to infection is an effective marker for diagnosis of latent and active tuberculosis.
Sci Rep
November 2024
Division of Infection and Global Health, School of Medicine, University of St Andrews, St Andrews, KY16 9TF, UK.
RNA sequencing and microarray analysis revealed transcriptional markers expressed in whole blood can differentiate active pulmonary TB (ATB) from other respiratory diseases (ORDs), and latent TB infection (LTBI) from healthy controls (HC). Here we describe a streamlined reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay that could be applied at near point-of-care for diagnosing and distinguishing ATB from ORDs and LTBI from HC. A literature review was undertaken to identify the most plausible host-gene markers (HGM) of TB infection.
View Article and Find Full Text PDFA modified multiple-criteria decision-making approach based on a protein-protein interaction network to diagnose latent tuberculosis.
BMC Med Inform Decis Mak
October 2024
Department of Biomedical Engineering, School of Advanced Medical Technology, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: DNA microarrays provide informative data for transcriptional profiling and identifying gene expression signatures to help prevent progression of latent tuberculosis infection (LTBI) to active disease. However, constructing a prognostic model for distinguishing LTBI from active tuberculosis (ATB) is very challenging due to the noisy nature of data and lack of a generally stable analysis approach.
Methods: In the present study, we proposed an accurate predictive model with the help of data fusion at the decision level.
Alterations in purine and pyrimidine metabolism associated with latent tuberculosis infection: insights from gut microbiome and metabolomics analyses.
mSystems
November 2024
Department of Biostatistics, School of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, China.
Article Synopsis
- * The study analyzed fecal samples from healthy controls, LTBI, and ATB patients, finding significant differences in gut bacterial diversity and microbial communities, with ATB patients showing notably reduced bacterial diversity.
- * Additionally, metabolic pathways related to purine and pyrimidine degradation were upregulated in LTBI and ATB patients, with specific metabolites identified that could distinguish between LTBI and healthy controls, indicating a link between gut microbiome changes and LTBI pathogenesis.
Antibodies as key mediators of protection against .
Front Immunol
September 2024
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States.
Tuberculosis (TB) is caused by infection with the bacterial pathogen (M.tb) in the respiratory tract. There was an estimated 10.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!